Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03495817 · ClinicalTrials.gov registry record · Phase 2
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
A Phase 2 study of Androgenetic Alopecia, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 3
- Study locations
NCT03495817: Completed Phase 2 study of Androgenetic Alopecia, sponsored by Aclaris Therapeutics.
NCT03495817 is a Phase 2 study of Androgenetic Alopecia that has completed, run by Aclaris Therapeutics. The registered enrollment target is 31 participants, below the 163-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03495817, a Phase 2 study of Androgenetic Alopecia, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 3
- Study locations
Study Summary
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
Primary Outcome
Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.
Conditions Studied
Interventions
- DRUG ATI-50002
Study Locations (3)
Colorado
- Aclaris Investigational Site - Denver
Oregon
- Aclaris Investigational Site - Portland
Texas
- Aclaris Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 2 |
What the finished NCT03495817 record still lists
NCT03495817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 163-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which ATI-50002 is the first listed.
NCT03495817 reports a single indexed study location in Colorado, Oregon, Texas.
Frequently Asked Questions
What is clinical trial NCT03495817 about?
NCT03495817 is a clinical study titled "A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution". Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
What is the current status of trial NCT03495817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2018-03-22. Estimated completion is 2019-10-30.
What conditions does trial NCT03495817 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT03495817?
The interventions under investigation include: ATI-50002 (DRUG).
Who is sponsoring clinical trial NCT03495817?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03495817 being conducted?
This trial has 3 study locations across Colorado, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03495817's enrollment target sits among peer trials
31 13th of 16 higher than 4 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
COMPLETED · Phase 2
-
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
COMPLETED · Phase 2
-
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI